Surgery for pre- and minimally invasive lung adenocarcinoma

医学 外科 腺癌 解剖(医学) 存活率 淋巴结 回顾性队列研究 转移 楔形切除术 切除术 癌症 内科学
作者
Yang Zhang,Xiangyi Ma,Xuxia Shen,Shengping Wang,Yuan Li,Hong Hu,Haiquan Chen
出处
期刊:The Journal of Thoracic and Cardiovascular Surgery [American Association for Thoracic Surgery]
卷期号:163 (2): 456-464 被引量:35
标识
DOI:10.1016/j.jtcvs.2020.11.151
摘要

Adenocarcinoma in situ (AIS) and minimally invasive adenocarcinoma (MIA) are the pre- and minimally invasive forms of lung adenocarcinoma. We aimed to investigate safety results and survival outcomes following different types of surgical resection in a large sample of patients with AIS/MIA.Medical records of patients with lung AIS/MIA who underwent surgery between 2012 and 2017 were retrospectively reviewed. Clinical characteristics, surgical types and complications, recurrence-free survival, and overall survival were investigated.A total of 1644 patients (422 AIS and 1222 MIA) were included. The overall surgical complication rate was significantly lower in patients receiving wedge resection (1.0%), and was comparable between patients undergoing segmentectomy (3.3%) or lobectomy (5.6%). Grade ≥ 3 complications occurred in 0.1% of patients in the wedge resection group, and in a comparable proportion of patients in the segmentectomy group (1.5%) and the lobectomy group (1.5%). There was no lymph node metastasis. The 5-year recurrence-free survival rate was 100%. The 5-year overall survival rate in the entire cohort was 98.8%, and was comparable among the wedge resection group (98.8%), the segmentectomy group (98.2%), and the lobectomy group (99.4%).Sublobar resection, especially wedge resection without lymph node dissection, may be the preferred surgical procedure for patients with AIS/MIA. If there are no risk factors, postoperative follow-up intervals may be extended. These implications should be validated in further studies.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
科目三应助舒适的梦玉采纳,获得10
刚刚
烟花应助Yuanyuan采纳,获得10
刚刚
1秒前
Cell发布了新的文献求助10
1秒前
2秒前
所所应助踏实大侠采纳,获得10
3秒前
坚强的初夏完成签到,获得积分20
3秒前
3秒前
科研混子完成签到,获得积分10
3秒前
3秒前
4秒前
4秒前
灵允发布了新的文献求助10
5秒前
Jorna完成签到,获得积分10
5秒前
所所应助Chemvenus采纳,获得10
6秒前
jack发布了新的文献求助10
6秒前
JEFF发布了新的文献求助10
6秒前
科研混子发布了新的文献求助10
6秒前
英姑应助彩色的不惜采纳,获得10
7秒前
汉堡包应助乐正秋凌采纳,获得10
7秒前
7秒前
迷路访云发布了新的文献求助10
7秒前
科研通AI2S应助Bear采纳,获得30
8秒前
8秒前
高高难破完成签到,获得积分10
8秒前
9秒前
应疾发布了新的文献求助10
9秒前
9秒前
9秒前
XiaoJie发布了新的文献求助10
9秒前
传奇3应助科研小飞侠采纳,获得10
10秒前
清秀的猎豹完成签到 ,获得积分10
10秒前
彭于晏应助陈静采纳,获得10
11秒前
灵允完成签到,获得积分10
11秒前
12秒前
12秒前
13秒前
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Handbook of pharmaceutical excipients, Ninth edition 5000
Aerospace Standards Index - 2026 ASIN2026 3000
Digital Twins of Advanced Materials Processing 2000
Polymorphism and polytypism in crystals 1000
Signals, Systems, and Signal Processing 610
Discrete-Time Signals and Systems 610
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 纳米技术 有机化学 物理 生物化学 化学工程 计算机科学 复合材料 内科学 催化作用 光电子学 物理化学 电极 冶金 遗传学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 6040134
求助须知:如何正确求助?哪些是违规求助? 7774639
关于积分的说明 16229674
捐赠科研通 5186237
什么是DOI,文献DOI怎么找? 2775285
邀请新用户注册赠送积分活动 1758278
关于科研通互助平台的介绍 1642075